Healthcare Management ENHERTU Granted Priority Review in the US for Patients with HER2 Low Metastatic Breast Cancer AIT News Desk Jul 25, 2022 Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU is the first HER2 directed therapy to demonstrate a survival…